Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br Limitations br Due to the complexity

    2022-09-01


    Limitations
    Due to the complexity and heterogeneity of lymphoid malignancies, as well as the deepening understanding of lymphoma, there have been many changes in the coding schema of lymphoma subtypes over time. New subtypes have been added as scientific knowledge of the disease expands, and some subtypes are re-categorized as entity definitions are modified. Such changes might influence the classification of NHL across the study Necrosulfonamide and impact the results of our analyses. The lack of surveillance data on recurrence in the SEER registries is also a limitation of this analysis. As more therapies are developed for second relapses and beyond, the relationships between recurrence and mortality has diminished, especially in FL. For more aggressive diseases like DLBCL, the capture of recurrence is critical since access to potentially curative therapies such as stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy may vary by SES and insurance status. Another limitation of this analysis was the amount of missing data on stage (5%-13%) and B symptoms (>30%). Future research should strive to enhance population-based datasets to corroborate these results and augment registry data for research question important to a catchment area. In addition, some NHL and DLBCL subtypes are particularly rare or have Necrosulfonamide an extremely low incidence in certain racial groups, resulting in a lack of sample size to provide robust results. Future research should strive to enhance population-based datasets to corroborate these results and augment registry data for research questions important to a catchment area. Additional biological characterization of patient samples using modern genomics based on recently published approaches41-44 are needed to understand the relationships between biological factors and other determinants of lymphoma outcomes.
    Conclusion
    Our analyses indicate that racial disparities exist in NHL incidence rates, disease presentation in DLBCL and FL, and survival outcomes for DLBCL patients in Georgia. However, the factors nektonic organisms account for racial disparities remain unclear, and further research is essential for clarifying possible mechanisms. Although our study harbors some limitations, our findings provide a better understanding of regional NHL racial disparities. Ongoing research in necessary to facilitate the development of targeted interventions and strategies to overcome the existing NHL disparities in a catchment region.
    Clinical Practice Points
    · Most current research has explored racial disparities in lymphoma at a national level. This study sought to identify and describe racial disparities in non-Hodgkin lymphoma in a specific catchment area where its findings could be used to implement new clinical practices aimed at addressing these disparities.
    ACCEPTED MANUSCRIPT
    · Black patients in Georgia with DLBCL were more likely than Whites to present with stage III/IV disease and B symptoms and had significantly worse 2-year and 5-year relative survival.
    · Regional information on racial differences in lymphoma incidence and presentation can help to inform future clinical practices directed at improving outcomes in poor-risk populations.
    ACCEPTED MANUSCRIPT
    References 1.– Siegel–RL,–Miller–KD,–Jemal–A.–Cancer–statistics,–2019.–CA–Cancer–J–
    US–lymphoid–malignancy–statistics–by–World–Health–Organization–subtypes.–CA–
    3.– Flowers–CR,–Fedewa–SA,–Chen–AY,–et–al.–Disparities–in–the–early–adoption–
    of–chemoimmunotherapy–for–diffuse–large–B-cell–lymphoma–in–the–United–States.–
    4.– Flowers–CR,–Nastoupil–LJ.–Socioeconomic–disparities–in–lymphoma.–Blood.–